Clinically significant interactions with drugs used in the treatment of tuberculosis.
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Fluoroquinolones for treating tuberculosisRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Clinical considerations in study designs that use cotinine as a biomarker.Drug interactions in the management of HIV infection.The pregnane X receptor in tuberculosis therapeutics.Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like culturesAn Update on Drug-induced Liver Injury.Emerging drugs for the treatment of tuberculosis.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Drug metabolism and drug interactions: potential application to antituberculosis drugs.A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents.Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality.Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.'A most malignant malady': a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma.Comparative Modulation of Levels of Oxidative Stress in the Liver of Anti-Tuberculosis Drug Treated Wistar Rats by Vitamin B12, Beta-Carotene, and Spirulina fusiformis: Role of NF-κB, iNOS, IL-6, and IL-10.Tuberculous meningitis in a lung transplanted patient.Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population.Improving treatment outcome assessment in a mouse tuberculosis model.
P2860
Q24202081-9030C2C1-3B97-4851-A6E2-C0FE4A08D3A8Q24242773-41765A72-E270-407B-A5EE-EA66956E45CFQ25255438-9FA02E38-E0A1-4B2F-9862-02BB0417203EQ26771997-95256FA5-0A8E-4D5C-A33B-7A9C81BB7C73Q34704814-1AEAD46B-4402-407A-ADA5-AC15F439A7D5Q35015993-1E0AD515-0365-4274-9A07-DBE9B8733D86Q35207903-245EA5EB-EED7-4380-8F93-BB8C76FB6725Q36066083-B1423B7B-38B2-46C5-8222-99318B653FB6Q36451492-66269E44-0132-4774-9DE3-B405D38E61E6Q36484652-1FC57FBA-D19D-4827-BBEA-F3DD2AA7C133Q37613520-AC5F5434-72CA-4AE1-AB0F-987B365C61EDQ37792105-422B3FF7-2DEE-4F25-BAB9-F970349BCC79Q37810480-9848EB9F-9179-43D7-B13E-20ECA4F13D3DQ37810481-DF74205C-9E53-4447-9D9E-7601F3E6F0FCQ38369608-CB5D5174-90B5-4DBF-9201-1CF0ACC71A5AQ38502286-13B6AD87-987F-4233-BE08-143D5EC6AD6CQ38666266-1895EB77-0345-490A-85DA-5749B40D5F3AQ38977166-A81C4AEC-1662-42DC-87C7-3B84A30FF964Q40319338-0D49263B-B624-4B72-87B3-926B329A7216Q42963305-DB9AA6C0-1685-4548-8ED1-5E8AADD616EAQ45909196-79564E99-ED25-41FB-B6DC-32A68FABC111Q47749022-DCE23B78-110D-4E18-A6A5-24097BDBDBE3Q48306306-A0CACF39-DE65-4535-AB12-1D636B2CEF49Q48537908-51C99FF0-31E0-4DD1-8C58-026BA5239EC6Q51653421-57A31526-9DE8-4FBF-AC12-4A9E14FB4003Q54239058-160F4DC3-2EFE-4DE4-83BB-E3F800B17729
P2860
Clinically significant interactions with drugs used in the treatment of tuberculosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@ast
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@en
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@nl
type
label
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@ast
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@en
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@nl
prefLabel
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@ast
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@en
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@nl
P1433
P1476
Clinically significant interactions with drugs used in the treatment of tuberculosis.
@en
P2093
P2860
P304
P356
10.2165/00002018-200225020-00005
P577
2002-01-01T00:00:00Z
P5875
P6179
1048239759